Omni Bio Pharmaceutical to Present at Noble Financial Capital Markets' Eighth ... MarketWatch (press release) Novel discoveries made at UCD indicate that AAT has the potential to address a variety of indications in the areas of diabetes, transplant rejection and bacterial and viral disorders. Omni Bio is also a significant investor in BioMimetix Pharmaceutical ... |
